American Society of Hirudotherapy

Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects

Research article published in Molecular aspects of medicine (1995)

Last Updated: March 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Genomics & ProteomicsClinical TrialsAscenzi P et al. · Molecular aspects of medicine, 1995

Summary

Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects.

Why This Matters for Hirudotherapy

Expands the genomic and molecular understanding of medicinal leeches and their bioactive repertoire.

Citation

Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects.

Ascenzi P et al. · Molecular aspects of medicine, 1995

DOI

Added to ASH library: March 18, 2026 · Site last updated: March 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.

Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects | ASH